Track topics on Twitter Track topics that are important to you
Published on BioPortfolio: 2019-04-18T12:14:32-0400
To assess the efficacy of multiple dupilumab (REGN668/ SAR231893) dose-regimens, compared to placebo, in adult patients with moderate-to-severe atopic dermatitis (AD).
This is a randomized, double-blind, placebo-controlled, parallel group study to confirm the efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis...
This is a randomized, double-blind, placebo-controlled, parallel-group study to confirm the efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis...
This is a single-arm, open-label study, which will examine the effect of dupilumab on the immunologic and genetic environment within atopic dermatitis lesions.
The purpose of this study is to understand the effect that T helper 2 (Th2) blockade has on well-described pathophysiological features of Atopic Dermatitis (AD), for example: barrier, epid...
Dupilumab has demonstrated efficacy in atopic dermatitis (AD) , asthma , perennial allergic rhinitis and chronic sinusitis . The objectives of this prospective observational, single-centre study were ...
Higher rates of conjunctivitis have been reported in atopic dermatitis (AD) patients treated with dupilumab, an anti-interleukin (IL)-4Rα antibody inhibiting IL-4 and IL-13, compared to patients trea...
Dupilumab is an interleukin-4-receptor inhibitor indicated in recalcitrant moderate-to-severe atopic dermatitis (1). Atopic dermatitis (AD) is a predominantly type 2-axis immune disorder, whereas alle...
Dupilumab is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials.
Atopic dermatitis (AD) is associated with changes in skin bacterial microbiome. Emollient treatment induces change in bacterial microbiome in AD, but its effect on fungal microbiome ("mycobiome") and ...
A disseminated vesicular-pustular eruption caused by the herpes simplex virus (HERPESVIRUS HOMINIS), the VACCINIA VIRUS, or Varicella zoster (HERPESVIRUS 3, HUMAN). It is usually superimposed on a preexisting, inactive or active, atopic dermatitis (DERMATITIS, ATOPIC).
The widespread involvement of the skin by a scaly, erythematous dermatitis occurring either as a secondary or reactive process to an underlying cutaneous disorder (e.g., atopic dermatitis, psoriasis, etc.), or as a primary or idiopathic disease. It is often associated with the loss of hair and nails, hyperkeratosis of the palms and soles, and pruritus. (From Dorland, 27th ed)
Antigens from the house dust mites (DERMATOPHAGOIDES), mainly D. farinae and D. pteronyssinus. They are proteins, found in mite feces or mite extracts, that can cause ASTHMA and other allergic diseases such as perennial rhinitis (RHINITIS, ALLERGIC, PERENNIAL) and atopic dermatitis (DERMATITIS, ATOPIC). More than 11 groups of Dermatophagoides ALLERGENS have been defined. Group I allergens, such as Der f I and Der p I from the above two species, are among the strongest mite immunogens in humans.
A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.
Rare autosomal recessive disease with variable expressions. Clinical features of the disease include variable ICHTHYOSIFORM ERYTHRODERMA, CONGENITAL; bamboo hair (trichorrhexis invaginata); and ATOPIC DERMATITIS. The disease is caused by mutations in the SPINK5 gene.